YALE UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1701-10-09

Employees: 10K

Market Cap: -

Website: http://www.yale.edu

Clinical Trials

Combining Varenicline and Guanfacine for Smoking Cessation

Phase 2

Recruiting

Conditions: Smoking Cessation

Interventions: Drug: Varenicline
Drug: Guanfacine ER

First Posted Date: 2019-12-13

Last Posted Date: 2025-02-11

Lead Sponsor: Yale University

Target Recruit Count: 140

Registration Number: NCT04198116

Locations: 🇺🇸
Yale University, New Haven, Connecticut, United States

vDPP Facilitated With Community Care Coordination

Not Applicable

Completed

Conditions: Diabetes Prevention

Interventions: Behavioral: vDPP

First Posted Date: 2019-12-12

Last Posted Date: 2024-11-18

Lead Sponsor: Yale University

Target Recruit Count: 96

Registration Number: NCT04195477

Locations: 🇺🇸
Griffin Hospital, Derby, Connecticut, United States
🇺🇸
Yale University, New Haven, Connecticut, United States

Effect of Physician Race and Gender on Simulated Patients' Ratings

Not Applicable

Completed

Conditions: Physician-Patient Relations
Bias, Sex
Patient Satisfaction
Bias, Racial

Interventions: Behavioral: Simulated White Male Physician
Behavioral: Simulated White Female Physician
Behavioral: Simulated Black Male Physician
Behavioral: Simulated Black Female Physician

First Posted Date: 2019-12-09

Last Posted Date: 2020-07-21

Lead Sponsor: Yale University

Target Recruit Count: 3592

Registration Number: NCT04190901

Locations: 🇺🇸
Yale University, New Haven, Connecticut, United States

Neurofeedback in Individuals With Substance Use Disorders

Not Applicable

Terminated

Conditions: Opioid-Related Disorders

Interventions: Device: Experimental feedback
Device: Control feedback
Device: fMRI

First Posted Date: 2019-12-05

Last Posted Date: 2024-03-26

Lead Sponsor: Yale University

Target Recruit Count: 12

Registration Number: NCT04188288

Locations: 🇺🇸
Yale New Haven Hospital, New Haven, Connecticut, United States

Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor

Phase 2

Withdrawn

Conditions: Transitional Cell Carcinoma

Interventions: Drug: Pembrolizumab and Ramucirumab

First Posted Date: 2019-11-27

Last Posted Date: 2022-02-22

Lead Sponsor: Yale University

Registration Number: NCT04179110

Locations: 🇺🇸
Yale University, New Haven, Connecticut, United States

Coordinating Opioid Use Treatment Through Medical Management With Infection Treatment (Project COMMIT)

Not Applicable

Completed

Conditions: Opioid-use Disorder

Interventions: Other: ID/LAB
Other: TAU

First Posted Date: 2019-11-27

Last Posted Date: 2025-04-03

Lead Sponsor: Yale University

Target Recruit Count: 171

Registration Number: NCT04180020

Locations: 🇺🇸
Yale New Haven Hospital, New Haven, Connecticut, United States
🇺🇸
Prisma Health, Greenville, South Carolina, United States
🇺🇸
Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States

Pharmacokinetics and Hepatic Safety of EGCG

Phase 1

Completed

Conditions: Uterine Fibroids

Interventions: Dietary Supplement: Epigallocatechin gallate (EGCG)
Drug: Clomiphene Citrate
Drug: Letrozole

First Posted Date: 2019-11-26

Last Posted Date: 2023-06-05

Lead Sponsor: Yale University

Target Recruit Count: 39

Registration Number: NCT04177693

Locations: 🇺🇸
Johns Hopkins Medicine, Baltimore, Maryland, United States

Pre-IVF Treatment With a GnRH Antagonist in Women With Endometriosis

Phase 3

Completed

Conditions: Infertility
Endometriosis

Interventions: Other: Placebo or SOC IVF
Drug: Elagolix 200 MG

First Posted Date: 2019-11-21

Last Posted Date: 2025-06-04

Lead Sponsor: Yale University

Target Recruit Count: 103

Registration Number: NCT04173169

Locations: 🇺🇸
Yale School of Medicine Dept.of Ob/Gyn & Reproductive Sciences, New Haven, Connecticut, United States
🇺🇸
University of Colorado Department of Obstetrics & Gynecology, Aurora, Colorado, United States
🇺🇸
Duke Fertility, Morrisville, North Carolina, United States

and more 2 locations

A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL)

Phase 1

Completed

Conditions: CTCL

Interventions: Drug: ABT-199 (venetoclax)

First Posted Date: 2019-11-21

Last Posted Date: 2021-06-25

Lead Sponsor: Yale University

Target Recruit Count: 4

Registration Number: NCT04171791

Locations: 🇺🇸
Yale New Haven Hospital / Smilow Cancer Center, New Haven, Connecticut, United States

Evaluating the Feasibility and Efficacy of a Real-time Smoking Intervention Using Wearable Technology

Not Applicable

Completed

Conditions: Tobacco Use Cessation

Interventions: Behavioral: Real-Time Smoking Intervention
Behavioral: Standard Treatment

First Posted Date: 2019-11-21

Last Posted Date: 2023-02-13

Lead Sponsor: Yale University

Target Recruit Count: 58

Registration Number: NCT04172623

Locations: 🇺🇸
Yale University, New Haven, Connecticut, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy